J&J taps German Merck to market Invokana in China

J&J taps German Merck to market Invokana in China

Source: 
Biopharma Dive
snippet: 

Johnson & Johnson's Xian Janssen Pharmaceuticals has inked a dealwith Merck KGaA to launch its diabetes drug Invokana in China, where the drug gained approval in September 2017. Financial details of the deal were not released.